Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Journal for immunotherapy of cancer·2026

Same author

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Cell·2026

Same author

Bringing in vivo CAR to the clinic: Promise, pitfalls, and questions to ask.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.

British journal of haematology·2026

Same author

Alpha-gal sensitization and allergic blood transfusion reactions: a scoping review.

Journal of translational medicine·2026

Same author

Patient and Physician Experiences in Immune Thrombocytopenia.

Advances in therapy·2026

Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026

Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026

Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026

Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026

Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026

Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Improving CAR T cell therapy by optimizing critical quality attributes.

Opal L Reddy, David F Stroncek, Sandhya R Panch

Seminars in Hematology

|September 7, 2020

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR)-T cell therapy shows promise for blood cancers but requires manufacturing optimization. This review addresses key variables in CAR-T cell production to improve safety, efficacy, and consistency for better patient outcomes.

Keywords:

CAR-T cells Critical quality attributes Manufacturing

More Related Videos

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Dec 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

Immunotherapy
Cellular Therapy
Hematologic Oncology

Background:

Chimeric antigen receptor (CAR)-T cell therapy offers significant benefits for hematologic malignancies, particularly relapsed/refractory B cell leukemia and lymphoma.
Despite successes, CAR-T cell therapy is not universally effective and can cause toxicities.
Optimizing the manufacturing process is crucial for enhancing the clinical utility of CAR-T cell therapies.

Purpose of the Study:

To review and identify critical manufacturing variables that influence CAR-T cell product quality.
To discuss strategies for optimizing CAR-T cell manufacturing to improve safety, purity, potency, consistency, and durability.

Main Methods:

Review of current literature on CAR-T cell manufacturing processes.
Analysis of how manufacturing variability impacts critical quality attributes.
Identification of key steps and parameters in CAR-T cell production.

Main Results:

Manufacturing processes for CAR-T cells are complex and prone to variability.
Variability in manufacturing can compromise essential product attributes.
Optimizing manufacturing is key to enhancing clinical outcomes.

Conclusions:

Standardizing and optimizing CAR-T cell manufacturing is essential for improving therapeutic efficacy and patient safety.
Addressing manufacturing challenges will lead to more consistent and durable CAR-T cell products.
Further research into manufacturing optimization will advance the field of CAR-T cell therapy.